Trial Profile
Randomized phase II study of two induction treatments of melphalan, prednisolone, plus bortezomib, JCOG-MPB versus modified PETHEMA-MPB, in elderly patients or non-elderly patients refusing transplant with untreated symptomatic myeloma (JCOG1105, IMPROVE-MPB study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2022
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Melphalan (Primary) ; Prednisolone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms IMPROVE-MPB
- 27 Aug 2022 Status changed from active, no longer recruiting to completed.
- 01 Dec 2021 Results (n=82) assessing specific HLA alleles associated with Btz-related toxicities and treatment responses to Btz-containing therapy among Japanese patients with MM published in the Cancer Science
- 21 Jun 2020 Results (n=79) exploratory analysis of single assessment criteria, presented at the 25th Congress of the European Haematology Association.